search
Back to results

Comparing the Baerveldt and Paul Glaucoma Drainage Devices and Their Effects on the Corneal Endothelium

Primary Purpose

Glaucoma

Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Surgery/implantation
Sponsored by
Oogziekenhuis Rotterdam
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Glaucoma

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18 - 75 years.
  • Informed consent.
  • Caucasian ethnicity (to facilitate comparison of results with those of earlier work). Ethnicity will be based on self-reported origin of subject and/or parents.
  • Primary open-angle glaucoma, pseudoexfoliative glaucoma, or pigmentary glaucoma.

Exclusion Criteria:

  • Normal pressure glaucoma.
  • History of ocular surgery (e.g. intraocular or strabismus surgery, tenon's capsule or conjunctiva surgery, cyclodestructive procedures etc).
  • History of ocular comorbidity (e.g. active uveitis, proliferative diabetic retinopathy).
  • Pseudophakia.
  • Functionally monocular patients.
  • Need for glaucoma surgery combined with other ocular procedures (i.e. cataract surgery, keratoplasty, or retinal surgery) or an anticipated need for additional ocular surgery.
  • Narrow anterior chamber angle.
  • Best corrected visual acuity less than 0.1.
  • Severe blepharitis.

Sites / Locations

  • Oogziekenhuis RotterdamRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Baerveldt glaucoma drainage device

Paul glaucoma drainage device

Arm Description

Outcomes

Primary Outcome Measures

Change of endothelial cell density (ECD).
ECD will be assessed at the center of the cornea and close to the tube.

Secondary Outcome Measures

Endothelial cell density (ECD).
ECD will be assessed at the center of the cornea and close to the tube.
Intraocular pressure.
Intraocular pressure.
Orthoptic assessment.
Prism cover test: total deviation at 30 cm; Goldmann: monocular ductions in 8 directions starting from primary position, binocular field of single vision.

Full Information

First Posted
April 19, 2022
Last Updated
December 12, 2022
Sponsor
Oogziekenhuis Rotterdam
search

1. Study Identification

Unique Protocol Identification Number
NCT05344651
Brief Title
Comparing the Baerveldt and Paul Glaucoma Drainage Devices and Their Effects on the Corneal Endothelium
Official Title
Comparing the Baerveldt and Paul Glaucoma Drainage Devices and Their Effects on the Corneal Endothelium
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 19, 2022 (Actual)
Primary Completion Date
June 2026 (Anticipated)
Study Completion Date
June 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Oogziekenhuis Rotterdam

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Rationale: The Baerveldt glaucoma drainage device (GDD) successfully reduces intraocular pressure but also involves a risk of corneal endothelial deterioration. Supposedly, the tip of a GDD tube with a thinner diameter, such as the Paul implant, will remain at a larger distance from the cornea and, thereby, cause less damage. Objective: To determine whether the Paul tube induces less damage to the corneal endothelium than the Baerveldt GDD. Study design: Randomized clinical trial. Study population: Phakic patients scheduled for surgical GDD implantation. Intervention: Either a Baerveldt or a Paul GDD implant. Main study parameters/endpoints: Endothelial cell density and tube position at 24 months. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The Paul GDD may have a less harmful effect on corneal endothelium. Otherwise, both GDDs will probably have a similar risk/benefit profile. The risks of study-related assessments are negligible, burden is low, extra time is about 5 x 1.5 h (total 7.5 h) in two years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glaucoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
160 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Baerveldt glaucoma drainage device
Arm Type
Active Comparator
Arm Title
Paul glaucoma drainage device
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Surgery/implantation
Intervention Description
The glaucoma drainage device consists of a plate and a tube. During surgery the plate is positioned underneath the conjunctiva and two extraocular muscles in the upper temporal quadrant of the eye. The tube is positioned in the anterior chamber.
Primary Outcome Measure Information:
Title
Change of endothelial cell density (ECD).
Description
ECD will be assessed at the center of the cornea and close to the tube.
Time Frame
Baseline and 2 years
Secondary Outcome Measure Information:
Title
Endothelial cell density (ECD).
Description
ECD will be assessed at the center of the cornea and close to the tube.
Time Frame
Baseline, 3, 6, 12, 24 months.
Title
Intraocular pressure.
Description
Intraocular pressure.
Time Frame
Baseline, 1, 3, 6, 12, 24 months.
Title
Orthoptic assessment.
Description
Prism cover test: total deviation at 30 cm; Goldmann: monocular ductions in 8 directions starting from primary position, binocular field of single vision.
Time Frame
Baseline, 3, 6, 12, 24 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age > 18 years. Informed consent. Caucasian ethnicity (to facilitate comparison of results with those of earlier work). Ethnicity will be based on self-reported origin of subject and/or parents. Primary open-angle glaucoma, pseudoexfoliative glaucoma, or pigmentary glaucoma. Exclusion Criteria: History of intraocular surgery (e.g. vitrectomy, cataract surgery, cyclodestructive procedures etc). History of ocular comorbidity (e.g. active uveitis, proliferative diabetic retinopathy). Pseudophakia. Functionally monocular patients. Need for glaucoma surgery combined with other ocular procedures (i.e. cataract surgery, keratoplasty, or retinal surgery) or an anticipated need for additional ocular surgery. Narrow anterior chamber angle. Best corrected visual acuity less than 0.1. Severe blepharitis.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rene J Wubbels
Phone
+31104023430
Email
r.wubbels@oogziekenhuis.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Susan Marinissen
Phone
+31104023449
Email
S.Marinissen@oogziekenhuis.nl
Facility Information:
Facility Name
Oogziekenhuis Rotterdam
City
Rotterdam
ZIP/Postal Code
3011BH
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rene J Wubbels, PhD
Phone
+31104023430
Email
r.wubbels@oogziekenhuis.nl
First Name & Middle Initial & Last Name & Degree
Ionela Popescu-Giovanitsas, MD
Phone
+31104023447
Email
I.Popescu@oogziekenhuis.nl
First Name & Middle Initial & Last Name & Degree
Jan Geert Bollemeijer, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Comparing the Baerveldt and Paul Glaucoma Drainage Devices and Their Effects on the Corneal Endothelium

We'll reach out to this number within 24 hrs